Nanox to Report Fourth Quarter 2025 Financial Results on April 20, 2026
NANO-X IMAGING LTD (Nanox) announced it will report its financial results for the fourth quarter ended December 31, 2025, before market open on Monday, April 20, 2026. A conference call will be hosted by Erez Meltzer (CEO) and Ran Daniel (CFO) at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can register for the call and access the live webcast through provided links on the Nanox Investor Relations website.
NNOX Q4'25 Earnings: EPS estimate is (0.19) USD
NANO-X IMAGING LTD (NNOX) is expected to announce its Q4'25 results on April 6, with an estimated revenue of $3.99 million USD and an EPS of ($0.19) USD. The article provides a detailed table of past and estimated revenue and EPS figures, highlighting quarter-over-quarter performance and surprise percentages. These financial insights are crucial for investors tracking NNOX's performance.
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
Nano-X Imaging Ltd. (Nanox) has announced a distribution agreement with Integrity Medical Service Inc. to deploy Nanox.ARC systems in Colorado, Wyoming, and parts of Kansas and Nebraska. This partnership aims to strengthen Nanox's regional presence and service support for its medical imaging technology, with a target of deploying 16 systems over two years. The collaboration leverages Integrity Medical Service's established network and service infrastructure to expand the reach of Nanox's innovative 3D digital tomosynthesis system in outpatient settings.
Nanox targets 16 imaging system deployments across 4 Western states
Nanox (NASDAQ: NNOX) has signed a distribution agreement with Integrity Medical Service Inc. to deploy its Nanox.ARC imaging system across Colorado, Wyoming, western Kansas, and Nebraska. The agreement targets the deployment of 4 systems in year 1 and 12 systems in year 2, leveraging Integrity's established presence and service infrastructure in the region. This partnership aims to expand Nanox's market penetration in outpatient settings, although deployment targets are subject to market conditions and customer adoption.
Nano-X Imaging's Unit Signs Distribution Deal With Integrity Medical Service for Imaging System
Nano-X Imaging's subsidiary, Nanox.ARC, has signed a distribution agreement with Integrity Medical Service for its Nanox.ARC system in several Central Asian countries. The deal, valued at up to $50 million over seven years, aims to deploy 500 Nanox.ARC systems, significantly expanding medical imaging access in the region. Integrity Medical Service has committed to an upfront payment and minimum purchase orders beginning in 2024.
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
Nanox has signed a distribution agreement with Integrity Medical Service, Inc. to expand the deployment of its Nanox.ARC systems in Colorado, Wyoming, Kansas, and Nebraska. This partnership aims to leverage Integrity Medical Service's established presence and service infrastructure to drive sales, implementation, and support for the Nanox.ARC system in outpatient imaging settings. The target is to deploy four systems in the first year and twelve in the second year, strengthening Nanox's regional presence and expanding access to its medical imaging technology.
Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems
Nanox, a medical imaging technology company, announced a distribution agreement with Integrity Medical Service Inc. to deploy its Nanox.ARC systems in Colorado, Wyoming, and parts of Kansas and Nebraska. This partnership aims to expand Nanox's regional presence and leverage Integrity Medical Service's established relationships and service infrastructure, with a target to deploy 16 systems over two years. The collaboration is expected to enhance access to advanced 3D imaging solutions, particularly in orthopedic and outpatient settings.
Nanox Signs Distribution Agreement with Elite Surgical Technologies to Deploy Nanox.ARC in Key U.S. Markets
Nanox Imaging Ltd. has signed a distribution agreement with Elite Surgical Technologies to deploy its Nanox.ARC system in key U.S. markets including Ohio, Indiana, Michigan, Pittsburgh, and West Virginia. This collaboration aims to enhance the adoption of advanced 3D imaging in orthopedic practices, particularly for monitoring bone regeneration and healing progression. The agreement anticipates the deployment of at least five Nanox.ARC systems in the first year and ten in the second, supporting Nanox's expansion in the U.S. orthopedic market.
Nanox subsidiary signs distribution deal with Elite Surgical By Investing.com
Nano-X Imaging Ltd. (NASDAQ:NNOX) announced that its U.S. subsidiary Nanox Impact Inc. has signed a distribution agreement with Elite Surgical Technologies. This deal will deploy the Nanox.ARC imaging system across Ohio, Indiana, Michigan, Pittsburgh, and West Virginia, focusing on orthopedic and post-surgical applications. The agreement anticipates the deployment of at least five systems in the first year and ten in the second, strengthening Nanox's U.S. market presence and expanding its channel partners.
Nanox (NNOX) Expands U.S. Reach with New Distribution Agreement
Nano-X Imaging (NNOX), through its subsidiary Nanox Impact, has formed a strategic partnership with Elite Surgical Technologies to broaden its U.S. market reach for the Nanox.ARC system. While this collaboration aims to boost the company's presence in orthopedic markets, Nano-X Imaging faces significant financial challenges including negative margins and low financial strength scores, despite strong revenue growth. The company's stock shows high volatility and is rated as a moderate buy by analysts, but its long-term sustainability hinges on addressing its financial performance.
Nanox Signs Distribution Agreement with Elite Surgical Technologies to Deploy Nanox.ARC in Key U.S. Markets
Nano-X Imaging Ltd. (NNOX) has signed a distribution agreement with Elite Surgical Technologies to deploy its Nanox.ARC digital tomosynthesis system across five key U.S. states. This collaboration aims to increase the adoption of advanced 3D imaging in orthopedic practices and surgical settings, particularly for monitoring bone regeneration. The agreement anticipates the deployment of at least five Nanox.ARC systems in the first year and ten in the second, subject to market conditions.
Medical imaging technology company Nano-X Imaging Ltd. (NASDAQ: NNOX) announced a strategic distribution partnership with Elite Surgical Technologies to promote the innovative Nanox.ARC digital X-ray system across several key healthcare markets in t
Nano-X Imaging Ltd. (NASDAQ: NNOX) has partnered with Elite Surgical Technologies to distribute its Nanox.ARC digital X-ray system in key U.S. healthcare markets. This collaboration aims to leverage Elite Surgical Technologies' distribution network to increase adoption of the Nanox.ARC system, which offers cost-effective and efficient digital imaging. The focus will be on densely populated medical regions along the East and West Coasts to strengthen Nanox's market presence.
Nanox subsidiary signs distribution deal with Elite Surgical
Nano-X Imaging Ltd. (NASDAQ:NNOX) announced that its U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with Elite Surgical Technologies. This deal aims to deploy the Nanox.ARC imaging system across several U.S. states, including Ohio, Indiana, Michigan, Pittsburgh, and West Virginia, specifically for orthopedic and post-surgical imaging applications. The agreement anticipates the deployment of at least five Nanox.ARC systems in the first year and ten in the second, further expanding Nanox's market reach.
A lower-radiation 3D imaging system expands into 5 U.S. markets
Nano-X Imaging (NNOX) has signed a distribution agreement with Elite Surgical Technologies to deploy its Nanox.ARC digital tomosynthesis system across five key U.S. markets: Ohio, Indiana, Michigan, Pittsburgh, and West Virginia. This expansion targets orthopedic and post-surgical imaging, with plans for at least five systems in the first year and ten in the second, contingent on market conditions and customer adoption. The FDA-cleared Nanox.ARC offers a lower-cost, reduced-radiation solution for 3D imaging compared to traditional CT scans.
Medical imaging technology company Nano-X Imaging Ltd. (NASDAQ: NNOX) announced a strategic distribution partnership with Elite Surgical Technologies to promote the innovative Nanox.ARC digital X-ray system across several key healthcare markets in t
Nano-X Imaging Ltd. (NASDAQ: NNOX) has partnered with Elite Surgical Technologies to distribute its Nanox.ARC digital X-ray system in key U.S. healthcare markets. This collaboration aims to leverage Elite Surgical Technologies' distribution network to increase the adoption of the Nanox.ARC system in clinical institutions. The partnership focuses on the East and West Coasts to provide affordable, advanced imaging solutions and strengthen Nanox's market position.
NNOX Q4'25 Earnings: revenue estimate is 3.99M USD
NANO-X IMAGING LTD (NNOX) is scheduled to release its Q4'25 earnings on April 06. Analysts estimate the company's revenue for the quarter to be $3.99 million USD, with an anticipated EPS of ($0.19) USD. The article also provides historical revenue and EPS data, along with estimates and surprises for previous quarters.
All Essential Information on NanoX Imaging (NNOX) Rating Raised to Buy
Nano-X Imaging Ltd. (NNOX) has received an upgrade to a Zacks Rank #2 (Buy), driven by optimistic revisions in its earnings projections for December 2025 where it is projected to report earnings of -$0.73 per share. This upgrade signifies growing confidence in the company's future financial performance and aligns with the Zacks ranking system, which prioritizes changes in earnings estimates as key indicators for short-term stock movements. The article highlights that such rating boosts often lead to increased investor interest and potential stock price appreciation due to improved fundamental outlooks.
[F-3/A] Nano-X Imaging Ltd. Amended Foreign Issuer Shelf Registration | NNOX SEC Filing - Form F-3/A
Nano-X Imaging Ltd. has filed an amended Form F-3 registration statement (F-3/A) to update an indenture form and its independent auditors' consent, without changing the main prospectus. This amendment clarifies corporate governance, particularly regarding exculpation, indemnification, and officers' insurance under Israeli law, including specific indemnification caps. The filing also notes that the registration contemplates sales "from time to time after the effective date."
Nano-X Imaging Showcases FDA-Cleared ARC X Rollout, Europe Commercialization Plans at Investor Conference
Nano-X Imaging presented their FDA-cleared ARC X rollout and European commercialization plans at an investor conference. The company highlighted its end-to-end imaging platform, including the Nanox.ARC system, and shared regulatory clearances obtained in the U.S. and Europe. Nano-X also detailed its business model, targeting various clinical settings with both outright purchase and pay-per-use options, and showcased its FDA/CE-approved AI tools for diagnostic analysis.
Nano-X Imaging (NNOX) CFO returns 39,474 ordinary shares to issuer
Nano-X Imaging Ltd.'s CFO, Daniel Ran, reported a disposition of 39,474 ordinary shares back to the company on March 18, 2026, at a price of $0.00 per share. This transaction was an issuer-related disposition, not an open-market sale, and involved shares underlying restricted share units. Following this, he directly holds 46,424 ordinary shares, with unvested portions tied to future anniversaries of the grant date.
Director Ronen Nehama details initial Nano-X Imaging (NNOX) share and option holdings
Nano-X Imaging director Ronen Nehama has filed an initial ownership report, detailing his equity position in the company. The filing reveals an option to purchase 50,000 ordinary shares at an exercise price of $17.63, expiring in 2033, along with direct holdings of ordinary shares and restricted share units that vest over twelve months from December 2025. This Form 3 provides transparency on Nehama's initial stake and aligns his incentives with the company's performance.
Nano-X Imaging (NNOX) Projected to Post Earnings on Monday
Nano-X Imaging (NNOX) is expected to announce its Q4 2025 earnings before market open on Monday, March 30th, with analysts projecting a loss of ($0.15) per share and $3.994 million in revenue. The company's stock has seen mixed analyst ratings but holds an average "Buy" consensus with a $7.00 target price. Institutional investors have a significant stake, with some, like UBS, recently increasing their holdings.
If You Invested $1,000 in Nano-X Imaging Ltd. (NNOX)
This article analyzes the historical performance of a $1,000 investment in Nano-X Imaging Ltd. (NNOX) over one, five, and ten years, comparing its returns to the S&P 500. It details NNOX's business model, which integrates medical imaging hardware, AI-based analytics, cloud infrastructure, and teleradiology services aimed at driving preventive healthcare. The company's financial data, corporate structure, and market position within the medical imaging industry are also provided.
[Form 3] Nano-X Imaging Ltd. Initial Statement of Beneficial Ownership
Nano-X Imaging Ltd. Director Kainan Noga has filed an Initial Statement of Beneficial Ownership (Form 3), detailing holdings that include ordinary shares, restricted stock units, and various stock options. Some shares are held directly, while others are held indirectly through I.B.L. Business Consulting Ltd., a company fully owned by Noga. The filing outlines the vesting schedules and expiration dates for the different stock options, with exercise prices ranging from $11.5200 to $64.6100.
Nano-X Imaging (NNOX) director discloses options and RSU holdings
Nano-X Imaging Ltd. director Michael Jackman has filed an initial ownership report (Form 3) detailing his equity stake in the company. The report reveals he holds stock options for 19,624 ordinary shares, fully vested and exercisable at an exercise price of $2.21, expiring in November 2029. Additionally, Jackman directly owns ordinary shares, including restricted share units granted in December 2025 that are set to vest in twelve equal monthly installments over one year.
Nano-X Imaging (NNOX) GM Ofir Koren details option and RSU holdings
Nano-X Imaging Ltd.'s General Manager of the ARC Division, Ofir Koren, has filed an initial statement detailing his beneficial ownership, including direct holdings of ordinary shares and stock options. The filing outlines stock options with exercise prices of $49.68, $17.63, and $11.52, expiring between 2031 and 2033, and restricted stock units granted in April 2024 and February 2026 that vest over time. This Form 3 filing serves as an initial ownership disclosure rather than a report of market purchases or sales.
Nano-X Imaging (NNOX) CEO Meltzer details option grants and shares
Nano-X Imaging Ltd.'s Form 3 filing discloses CEO Erez Meltzer's initial beneficial ownership. He directly owns 60,584 ordinary shares and holds multiple stock option grants with varying exercise prices, expiration dates, and vesting schedules, some fully vested and others vesting over time until 2028. This filing provides transparency on his equity holdings in the company.
Nano-X Imaging Ltd. Initial Statement of Beneficial Ownership
Nano-X Imaging Ltd.'s Chief Legal Officer, Marina Gofman Feler, filed an initial statement of beneficial ownership (Form 3) on March 18, 2026. This filing details her holdings, including stock options for 55,000 ordinary shares with various exercise prices and expiration dates, as well as 20,000 ordinary shares underlying restricted share units and 26,316 directly held ordinary shares. The document provides a breakdown of vesting schedules for the restricted share units and stock options.
Nano-X Imaging (NNOX) GM discloses stock option and RSU holdings
Dara James, GM of Nano-X Imaging's Source & Services Division, has filed an initial ownership report detailing stock options and restricted share units. The filing shows holdings of stock options with various exercise prices and expiration dates, as well as restricted share units granted February 5, 2026, which will vest over 12 and 24 months. This Form 3 filing is a statement of existing beneficial ownership, not a new transaction.
Nanox Expands in Latin America Through New Distribution Agreement
Nanox Imaging Ltd. has entered into an exclusive distribution agreement with Argentinian medical device distributor Intec SRL to commercialize its Nanox.ARC 3D medical imaging system in Argentina. This partnership aims to expand access to cost-effective 3D imaging solutions, particularly in Argentina's high-demand private healthcare sector. Intec SRL will handle all marketing, distribution, installation, and support, pending regulatory approvals.
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Nano-X Imaging Ltd. (Nanox) has partnered with Imperial Imaging Technology LLC to distribute its Nanox.ARC digital tomosynthesis system across six Southeastern U.S. states. This agreement aims to expand access to advanced musculoskeletal imaging directly within orthopedic practices, offering a lower-cost, reduced-radiation 3D imaging solution. The collaboration strengthens Nanox's market presence in the orthopedic sector and leverages Imperial Imaging's expertise in supporting clinical workflows.
Nanox Signs Distribution Agreement with Imperial Imaging
Nano-X Imaging Ltd. (Nanox) has signed a distribution agreement with Imperial Imaging Technology LLC to expand access to its Nanox.ARC multisource digital tomosynthesis system across six U.S. Southeast states. This partnership aims to bring advanced 3D imaging directly into orthopedic practices, improving continuity of care and clinical workflows by reducing the need for off-site imaging. Imperial Imaging will manage marketing, sales, and customer support, leveraging its strong relationships within the orthopedic community.
Nano-X Imaging (NASDAQ:NNOX) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reissued a "Buy" rating for Nano-X Imaging (NNOX) with a $5.00 price target, representing a potential 94.17% upside. The overall analyst consensus for NNOX is "Buy" with an average target price of $7.00. The company, which develops a digital X-ray imaging platform, currently trades around $2.58 with a market capitalization of $168.36 million, a negative P/E of -1.95, and institutional ownership of about 21.5%.
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Nano-X Imaging Ltd. (Nanox) has signed a distribution agreement with Imperial Imaging Technology LLC to expand the commercial rollout of its Nanox.ARC system across six U.S. Southeast states. This partnership aims to increase access to advanced musculoskeletal imaging directly within orthopedic practices, improving patient care efficiency and reducing costs. Imperial Imaging Technology will manage marketing, sales, and customer support, leveraging its strong presence and expertise in the orthopedic community.
3D orthopedic imaging closer to home: Nanox-Imperial deal spans Southeast
Nanox (NASDAQ: NNOX) has signed a distribution agreement with Imperial Imaging Technology to expand access to its Nanox.ARC digital tomosynthesis system across six U.S. Southeast states: Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida. Imperial will handle marketing, demonstrations, clinical evaluations, installations, and support for orthopedic and musculoskeletal practices. This partnership aims to bring advanced 3D orthopedic imaging closer to the point of care, reducing patient travel and improving clinical workflows, with Nanox.ARC DTS imaging being reimbursable under an existing CPT code without pre-authorization.
Nanox Signs Distribution Agreement with Imperial Imaging
Nano-X Imaging Ltd. (Nanox) has signed a distribution agreement with Imperial Imaging Technology LLC to expand the commercial rollout of its Nanox.ARC system across six U.S. Southeast states. This partnership strengthens Nanox's channel partner strategy in a significant orthopedic market, allowing for advanced musculoskeletal imaging directly within orthopedic practices. The collaboration aims to improve patient care efficiency and reduce administrative burden by keeping imaging closer to the point of care.
Nanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Nano-X Imaging Ltd. (NASDAQ: NNOX) announced a distribution agreement with Imperial Imaging Technology LLC to expand the commercial rollout of its Nanox.ARC system across the U.S. Southeast. This partnership aims to increase access to advanced musculoskeletal imaging directly within orthopedic practices, offering a cost-effective, lower-radiation 3D imaging solution. Imperial Imaging Technology will be responsible for marketing, sales, and customer support in Georgia, Alabama, Tennessee, North Carolina, South Carolina, and Northern Florida.
NNOX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Nano-X Imaging Ltd. (NNOX), including its income statement, balance sheet, and cash flow statement up to fiscal year 2024. It highlights key metrics such as revenue, EBITDA, net income, and various financial ratios, along with an assessment of the company's financial health, which is rated as moderate with a Piotroski F-Score of 3/9. The company reported a revenue of $11.3M with negative profitability and a cash runway of approximately 13 months.
NNOX Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for NNOX, focusing on upcoming Q4 2025 forecasts and historical earnings performance. Analysts project Q4 2025 revenue of $3.99M and an EPS of $-0.19, with estimates remaining unchanged over the past three months despite a significant stock price drop. The article also reviews past earnings reactions and discusses potential buying opportunities based on fundamental analysis.
Nano-X Imaging (NASDAQ:NNOX) Shares Up 0.8% - Here's Why
Shares of Nano-X Imaging (NASDAQ:NNOX) rose by 0.8% to $2.45 on Wednesday, despite trading volume being 44% below its daily average. The company has a mixed analyst consensus of "Buy" with a price target of $7.00, though some recent target reductions have occurred. Nano-X Imaging, a medical technology company specializing in digital X-ray imaging, has a market capitalization of $160.18 million and institutional investors hold approximately 21.5% of its stock.
NNOX Fundamental Analysis | NANO-X IMAGING LTD (NASDAQ:NNOX)
NANO-X IMAGING LTD (NNOX) has been assigned a fundamental rating of 3 out of 10 by ChartMill, indicating concerns regarding its profitability despite a strong health rating. The company's valuation is considered expensive, and while it shows a medium growth rate, it has reported negative net income and operating cash flow in recent years. Future projections suggest strong revenue and EPS growth, though valuation multiples like P/E are not calculable due to negative earnings.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has announced an exclusive distribution agreement with Intec SRL for its Nanox.ARC system in Argentina. This collaboration aims to expand access to cost-effective 3D medical imaging technology in Argentina's private healthcare sector. The Nanox.ARC system offers 3D imaging at a lower cost and reduced radiation compared to traditional CT scans.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has signed an exclusive distribution agreement with Intec SRL for its Nanox.ARC digital tomosynthesis system in Argentina. This partnership aims to expand access to cost-effective 3D medical imaging in Argentina's private healthcare sector. Intec SRL will handle marketing, distribution, installation, and support, contributing to Nanox's Latin American expansion strategy.
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
Nanox Imaging Ltd. has announced an exclusive distribution agreement with Intec SRL for its Nanox.ARC system in Argentina. This partnership aims to expand access to cost-effective 3D medical imaging solutions in Argentina's private healthcare sector. Intec SRL will handle marketing, distribution, installation, and support, facilitating broader availability of the Nanox.ARC system, pending regulatory approvals.
Nanox Expands its European Reach With New Distribution Partnership
Nanox Imaging Ltd. has expanded its European presence through a new strategic alliance with Adriamed d.o.o. Beograd, a medical device distributor in Southeast Europe. This collaboration aims to enhance access to cost-effective medical imaging solutions, specifically bringing the Nanox.ARC digital tomosynthesis system to healthcare providers in Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will be the exclusive partner for distribution, installation, and support of the Nanox.ARC in the region, leveraging their local expertise to broaden market penetration.
New 3D scan tech aims to cut costs, radiation for Argentine patients
Nanox (Nasdaq: NNOX) has announced an exclusive distribution agreement with Intec SRL for its Nanox.ARC digital tomosynthesis system in Argentina, dated February 19, 2026. This partnership aims to expand access to cost-effective 3D medical imaging, which offers significantly reduced radiation compared to traditional CT scans, within Argentina's private healthcare sector. The agreement covers marketing, distribution, installation, and support, with commercial sales contingent on regulatory approvals.
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
Nanox (Nasdaq: NNOX) announced it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) in Vienna from March 4-8, 2026. The company will also present new AI solutions, including FDA-cleared and CE-marked solutions for cardiac, bone, and liver analysis, as well as new data from the ADOPT study regarding AI-enabled vertebral fracture identification. This marks a significant step in Nanox's European market expansion, aiming to make advanced medical imaging more accessible and affordable.
Nanox Imaging to Showcase Nanox.ARC and AI Solutions at ECR 2026 in Vienna
NANO-X IMAGING LTD (Nanox) will feature its Nanox.ARC digital tomosynthesis system for the first time in Europe at the European Congress of Radiology (ECR) from March 4-8, 2026, in Vienna. The company will conduct live demonstrations of the CE-marked and FDA-cleared Nanox.ARC, which offers cost-effective 3D imaging with reduced radiation, and present new clinical data on lung cancer screening. Nanox will also highlight its AI solutions for analyzing CT scans for chronic disease detection and introduce new AI solutions for aortic valve calcification and body composition measurement.
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
Nanox announced it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions at the European Congress of Radiology (ECR) from March 4-8, 2026. The Nanox.ARC, a CE-marked and FDA-cleared system, offers 3D imaging at a lower cost and reduced radiation dose. The company will also highlight its FDA-cleared Nanox.AI solutions for chronic disease detection and present new clinical data from the ADOPT study.
FDA clearance lets Nanox systems give 3D, 2D views without extra radiation
Nanox (NNOX) has received FDA 510(k) clearance for its TAP2D image enhancement capability for Nanox.ARC and Nanox.ARC X tomosynthesis systems. This feature allows the generation of a clear 2D view from a single tomosynthesis scan without additional radiation exposure, integrating into existing workflows. The clearance is a pivotal step in Nanox's strategy to remove the "adjunct use" label in the U.S., aiming for standalone primary imaging, mirroring its CE Mark status in Europe.
